Compare · ARGX vs ITOS
ARGX vs ITOS
Side-by-side comparison of argenx SE (ARGX) and iTeos Therapeutics Inc. (ITOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ITOS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 45.1x ITOS ($1.23B).
- Over the past year, ARGX is up 51.2% and ITOS is up 1.4% - ARGX leads by 49.8 points.
- ARGX has hit the wire 5 times in the past 4 weeks while ITOS has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 9 for ITOS).
- Company
- argenx SE
- iTeos Therapeutics Inc.
- Price
- $882.63-1.03%
- $10.17+0.30%
- Market cap
- $55.32B
- $1.23B
- 1M return
- +12.11%
- +0.39%
- 1Y return
- +51.24%
- +1.40%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 9
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
iTeos Therapeutics Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest ITOS
- SEC Form 15-12G filed by iTeos Therapeutics Inc.
- SEC Form EFFECT filed by iTeos Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by iTeos Therapeutics Inc.
- Chief Operating Officer Call Matthew closing all direct ownership in the company (SEC Form 4)
- Chief Executive Officer Detheux Michel closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Lee David K
- Chief Medical Officer Feltquate David closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Mcgrath Yvonne closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Gall Matthew closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Hallal David